-

Zai Lab Announces Participation in Investor Conferences in September 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2025:

Cantor Global Healthcare Conference
Presentation: Thursday, September 4, 2025, 10:20 a.m. ET
Location: New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Tuesday, September 9, 2025, 2:35 p.m. ET
Location: New York, NY

Live webcasts will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of the events.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Contacts

For more information, please contact:

Investor Relations:
Christine Chiou
+1 (917) 886-6929
christine.chiou1@zailaboratory.com

Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media:
Shaun Maccoun
+1 (857) 270-8854
shaun.maccoun@zailaboratory.com

Xiaoyu Chen
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com

Industry:

Zai Lab Limited

NASDAQ:ZLAB
Release Versions
English

Contacts

For more information, please contact:

Investor Relations:
Christine Chiou
+1 (917) 886-6929
christine.chiou1@zailaboratory.com

Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media:
Shaun Maccoun
+1 (857) 270-8854
shaun.maccoun@zailaboratory.com

Xiaoyu Chen
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com

More News From Zai Lab Limited

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2025 financial results and provide recent corporate updates on February 26, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http:/...

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company’s 2026 strategic priorities and clinical development progress. These updates will be discussed as part of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. “Since our founding, we have intentionally built Zai Lab as a dual-engine company – combining a commercia...

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is li...
Back to Newsroom